AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21128879 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 476
Study 18370982 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized racemic albuterol
Number of subjects: 703
Study 18370982 — intervention group
Group type: COMPARATOR
Intervention: Nebulized racemic epinephrine
Number of subjects: 703
Study 16983056 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 13
Study 12728413 — intervention group
Group type: EXPERIMENTAL
Intervention: Predonated autologous blood
Number of subjects: 83
Study 12728413 — intervention group
Group type: COMPARATOR
Intervention: Postoperative unwashed blood salvage
Number of subjects: 83
Study 11044422 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 40
Study 11044422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8698945 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0
Study 8698945 — intervention group
Group type: COMPARATOR
Intervention: No hypnosis (Control)
Number of subjects: 0
Study 1353514 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PVP-I) bladder irrigation before catheter removal
Number of subjects: 264
Study 1353514 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PVP-I irrigation)
Number of subjects: 264
Study 6614059 — intervention group
Group type: EXPERIMENTAL
Intervention: New residences designed to be more normalizing
Number of subjects: 0
Study 6614059 — intervention group
Group type: COMPARATOR
Intervention: Older institutional buildings designed for more custodial care
Number of subjects: 0
Study 6614059 — intervention group
Group type: EXPERIMENTAL
Intervention: Social aspects of normalizing environments
Number of subjects: 0
Study 29713889 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix allograft (ADM)
Number of subjects: 25
Study 29713889 — intervention group
Group type: COMPARATOR
Intervention: Free gingival graft (FGG)
Number of subjects: 25
Study 28689915 — intervention group
Group type: EXPERIMENTAL
Intervention: Vita Enamic
Number of subjects: 93
Study 28689915 — intervention group
Group type: COMPARATOR
Intervention: Vitablocs Mark II
Number of subjects: 93
Study 28689915 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 93
Study 27119918 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (20 units)
Number of subjects: 73
Study 27119918 — intervention group
Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA (60 units)
Number of subjects: 73
Study 27119918 — intervention group
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA (20 units)
Number of subjects: 73
Study 24560063 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score (SS) tertiles (SS<7, 7 to 12, and >12)
Number of subjects: 2268
Study 24560063 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score (SS)
Number of subjects: 2268
Study 24560063 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who developed AKI
Number of subjects: 2268
Study 24560063 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score (SS) tertiles
Number of subjects: 2268
Study 21665116 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic stabilization (RS)
Number of subjects: 14
Study 21665116 — intervention group
Group type: COMPARATOR
Intervention: Passive stretching (PS)
Number of subjects: 14
Study 19573482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 to 160 mg/day, administered b.i.d.
Number of subjects: 62
Study 16979126 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse gram lectin (Dolichos biflorus agglutinin) skin prick test (SPT) at 100 microg/mL
Number of subjects: 48
Study 16979126 — intervention group
Group type: EXPERIMENTAL
Intervention: DBA-specific IgE detection by ELISA and dot-blot
Number of subjects: 48
Study 16979126 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine release (HR) assay using leukocytes
Number of subjects: 48
Study 16979126 — intervention group
Group type: EXPERIMENTAL
Intervention: Basophil HR by DBA
Number of subjects: 48
Study 16979126 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of food allergy to horse gram
Number of subjects: 48
Study 15219008 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal vancomycin (0.5 g of a 4% gel at 6-hour intervals)
Number of subjects: 84
Study 15219008 — intervention group
Group type: COMPARATOR
Intervention: Control group (selective decontamination protocol including polymyxin E, tobramycin, and amphotericin B)
Number of subjects: 84
Study 15219008 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal vancomycin
Number of subjects: 84
Study 10931808 — intervention group
Group type: EXPERIMENTAL
Intervention: Remnant-like lipoprotein particles (RLPs)
Number of subjects: 0
Study 10931808 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol
Number of subjects: 0
Study 10931808 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 0
Study 10931808 — intervention group
Group type: COMPARATOR
Intervention: Total triglyceride-rich lipoproteins (TGLs) and LDL
Number of subjects: 0
Study 9328328 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) treatment with IFN‐alpha2b (3 million units 3 times weekly for 12 months)
Number of subjects: 19
Study 9328328 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 19
Study 8222928 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacron bifurcation prostheses (with or without velours or gelatin impregnation)
Number of subjects: 100
Study 8222928 — intervention group
Group type: COMPARATOR
Intervention: Double velours prostheses
Number of subjects: 100
Study 8222928 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacron bifurcation prostheses (with gelatin impregnation)
Number of subjects: 100
Study 3759279 — intervention group
Group type: EXPERIMENTAL
Intervention: Euphylong (E)
Number of subjects: 12
Study 3759279 — intervention group
Group type: COMPARATOR
Intervention: Uniphyllin (U)
Number of subjects: 12
Study 4913623 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal doses of histamine acid phosphate
Number of subjects: 1
Study 4913623 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaximal doses of histamine acid phosphate
Number of subjects: 1
Study 4913623 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal doses of pentagastrin
Number of subjects: 1
Study 4913623 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaximal doses of pentagastrin
Number of subjects: 1
Study 31732851 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape juice (10 ml/kg/day)
Number of subjects: 14
Study 31732851 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (10 ml/kg/day)
Number of subjects: 14
Study 31234919 — intervention group
Group type: EXPERIMENTAL
Intervention: Tong‐luo Qu‐tong plaster administered externally for 14 days (two courses, once daily)
Number of subjects: 2000
Study 31234919 — intervention group
Group type: COMPARATOR
Intervention: Qi‐zheng Xiao‐tong plaster administered externally for 14 days (two courses, once daily)
Number of subjects: 2000
Study 31234919 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups will document adverse events related to clinical symptoms and signs and results of laboratory tests during the clinical trials.
Number of subjects: 2000
Study 28081543 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan/S‐1 (IRIS) therapy
Number of subjects: 127
Study 28081543 — intervention group
Group type: COMPARATOR
Intervention: S‐1 monotherapy
Number of subjects: 127
Study 25244676 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical OC sample (HOC)
Number of subjects: 52
Study 25244676 — intervention group
Group type: COMPARATOR
Intervention: Low OC symptoms control sample (LOC)
Number of subjects: 52
Study 23769807 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine plus normal saline solution
Number of subjects: 399
Study 23769807 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution only
Number of subjects: 399
Study 23769807 — intervention group
Group type: EXPERIMENTAL
Intervention: Less than 1 L intravenous fluids
Number of subjects: 399
Study 23769807 — intervention group
Group type: COMPARATOR
Intervention: Greater than 1 L intravenous fluids
Number of subjects: 399
Study 21668768 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin (100 μg)
Number of subjects: 56
Study 21668768 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (5 IU)
Number of subjects: 56
Study 19837206 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment (MT) + Cognitive Behavior Therapy (CBT)
Number of subjects: 83
Study 19837206 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary treatment (MT)
Number of subjects: 83
Study 16721304 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Number of subjects: 286
Study 16721304 — intervention group
Group type: COMPARATOR
Intervention: Advice from a physiotherapist
Number of subjects: 286
Study 14699021 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (CEE) 0.625 mg
Number of subjects: 44
Study 14699021 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (CEE) 0.3125 mg
Number of subjects: 44
Study 14699021 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (CEE) 0.625 mg and 0.3125 mg
Number of subjects: 44
Study 14699021 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 44
Study 11407293 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium-thiopental (Ro-Th) group
Number of subjects: 90
Study 11407293 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental-rocuronium (Th-Ro) group
Number of subjects: 90
Study 11407293 — intervention group
Group type: COMPARATOR
Intervention: Thiopental-succinylcholine (Th-Sx) group
Number of subjects: 90
Study 9209015 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemopreventive agents (specific agents not mentioned)
Number of subjects: 0
Study 9209015 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 8315422 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 50 mg/m2 on days 1 and 8 (every 3 weeks) with fluorouracil (5 FU) and cyclophosphamide 500 mg/m2 on day 1 of each course (group A)
Number of subjects: 141
Study 8315422 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin administered only on day 1 with fluorouracil (5 FU) and cyclophosphamide 500 mg/m2 on day 1 of each course (group B)
Number of subjects: 141
Study 2893637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 2893637 — intervention group
Group type: COMPARATOR
Intervention: Famotidine
Number of subjects: 0
Study 29343468 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin-A (BoNT-A) injections (200 units: 60 into each masseter and 40 into each temporalis)
Number of subjects: 23
Study 29343468 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 23
Study 27414159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 11
Study 27414159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 24714351 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg elemental iron
Number of subjects: 32
Study 24714351 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg elemental iron
Number of subjects: 32
Study 24714351 — intervention group
Group type: COMPARATOR
Intervention: Placebo (iron deficient)
Number of subjects: 32
Study 24714351 — intervention group
Group type: COMPARATOR
Intervention: Placebo (iron sufficient)
Number of subjects: 32
Study 24714351 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg and 80 mg elemental iron
Number of subjects: 32
Study 24714351 — intervention group
Group type: COMPARATOR
Intervention: Placebo (iron deficient) and Placebo (iron sufficient)
Number of subjects: 32
Study 22433756 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 0
Study 22433756 — intervention group
Group type: COMPARATOR
Intervention: FU/LV
Number of subjects: 0
Study 19484401 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser irradiation treatment (diode laser)
Number of subjects: 30
Study 19484401 — intervention group
Group type: COMPARATOR
Intervention: Topical fluoride treatment (protective varnish)
Number of subjects: 30
Study 19001202 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens, 0.625 mg/d
Number of subjects: 27347
Study 19001202 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus medroxyprogesterone acetate, 2.5 mg/d
Number of subjects: 27347
Study 19001202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27347
Study 17033273 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg metoprolol tartrate
Number of subjects: 12
Study 17033273 — intervention group
Group type: COMPARATOR
Intervention: 25 mg carvedilol
Number of subjects: 12
Study 12723464 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0
Study 12723464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11095086 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (n = 66)
Number of subjects: 137
Study 11095086 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 71)
Number of subjects: 137
Study 9055049 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment
Number of subjects: 400
Study 9055049 — intervention group
Group type: COMPARATOR
Intervention: Usual community physician care
Number of subjects: 400
Study 8229609 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral activated charcoal (OAC) therapy, 8.5 +/- 0.85 gms before meals
Number of subjects: 30
Study 8229609 — intervention group
Group type: COMPARATOR
Intervention: Control group (phototherapy only)
Number of subjects: 30
Study 2985395 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4-10 (single s.c. dose)
Number of subjects: 0
Study 2985395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2985395 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT
Number of subjects: 0
Study 30207079 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) at high frequency (three times/week)
Number of subjects: 53
Study 30207079 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) at high frequency (three times/week)
Number of subjects: 53
Study 30207079 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) at low frequency (two times/week)
Number of subjects: 53
Study 30207079 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) at low frequency (two times/week)
Number of subjects: 53
Study 30207079 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 53
Study 30207079 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 53
Study 26663540 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 μg Chromium picolinate (CrP) for 6 months
Number of subjects: 85
Study 26663540 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules for 6 months
Number of subjects: 85
Study 25126867 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks interval training (60‐79% HRmax) programme of between 45 and 60 minutes
Number of subjects: 245
Study 25126867 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 245
Study 22410037 — intervention group
Group type: EXPERIMENTAL
Intervention: Rusch intubation stylet tied to the NGT (group S)
Number of subjects: 80
Study 22410037 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C) - NGT inserted with patient's head in neutral position
Number of subjects: 80
Study 22410037 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 80
Study 20473540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF)
Number of subjects: 40
Study 20473540 — intervention group
Group type: COMPARATOR
Intervention: Sham pulsed electromagnetic field therapy (sham PEMF)
Number of subjects: 40
Study 18360659 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal initial therapy
Number of subjects: 30
Study 16737046 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant HBV vaccine (40 micrograms per dose) in HIV/AIDS patients with high CD4 count (group 1A)
Number of subjects: 60
Study 16737046 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant HBV vaccine (40 micrograms per dose) in HIV/AIDS patients with low CD4 count (group 1B)
Number of subjects: 60
Study 16737046 — intervention group
Group type: COMPARATOR
Intervention: Recombinant HBV vaccine (20 micrograms per dose) in normal healthy controls (group II)
Number of subjects: 60
Study 16737046 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant HBV vaccine in all groups (HIV-positive and controls)
Number of subjects: 60
Study 16737046 — intervention group
Group type: EXPERIMENTAL
Intervention: PHA stimulation in HIV-positive groups
Number of subjects: 60
Study 16737046 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant HBV vaccine in patients with high CD4 count
Number of subjects: 60
Study 16737046 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant HBV vaccine in patients with low CD4 count
Number of subjects: 60
Study 16737046 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant HBV vaccine in patients with CD4 count < 50
Number of subjects: 60
Study 12881821 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanic contractions (35Hz)
Number of subjects: 12
Study 12881821 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-Hz twitch contractions
Number of subjects: 12
Study 12881821 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz twitch contractions
Number of subjects: 12
Study 12881821 — intervention group
Group type: COMPARATOR
Intervention: Inactive leg (control)
Number of subjects: 12
Study 10688158 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg
Number of subjects: 36
Study 10688158 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg
Number of subjects: 36
Study 10688158 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 36
Study 10688158 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 36
Study 10688158 — intervention group
Group type: EXPERIMENTAL
Intervention: Both olanzapine and risperidone
Number of subjects: 36
Study 8813311 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound measurement of bladder wall thickness greater than 5 mm
Number of subjects: 184
Study 8813311 — intervention group
Group type: COMPARATOR
Intervention: Bladder wall thickness less than 3.5 mm
Number of subjects: 184
Study 1881582 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody OKT3
Number of subjects: 65
Study 1881582 — intervention group
Group type: COMPARATOR
Intervention: High-dose methylprednisolone
Number of subjects: 65
Study 6348424 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 day course of antibiotic prophylaxis (48 hours of intramuscular kanamycin and intravenous cephalothin)
Number of subjects: 160
Study 6348424 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 day course of antibiotic prophylaxis (48 hours of intramuscular kanamycin and intravenous cephalothin followed by 3 days of oral cephalexin)
Number of subjects: 160
Study 30289491 — intervention group
Group type: EXPERIMENTAL
Intervention: Phage cocktail (TM3 plus TM1, TM2, and TM4)
Number of subjects: 360
Study 30289491 — intervention group
Group type: EXPERIMENTAL
Intervention: Single phage (TM3)
Number of subjects: 360
Study 30289491 — intervention group
Group type: COMPARATOR
Intervention: 200 μL sterile PBS (control)
Number of subjects: 360
Study 30289491 — intervention group
Group type: COMPARATOR
Intervention: 200 μL of selected phage (TM3) (control)
Number of subjects: 360
Study 29863610 — intervention group
Group type: EXPERIMENTAL
Intervention: OctaplasLG
Number of subjects: 57
Study 29863610 — intervention group
Group type: COMPARATOR
Intervention: Standard FFP
Number of subjects: 57
Study 26977602 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning-focused CBT (PML)
Number of subjects: 159
Study 26977602 — intervention group
Group type: COMPARATOR
Intervention: Solution-focused CBT (SFT)
Number of subjects: 159
Study 26977602 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (PML and SFT)
Number of subjects: 159
Study 24119856 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 73
Study 24119856 — intervention group
Group type: COMPARATOR
Intervention: Nutritional education
Number of subjects: 73
Study 21917299 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy (quinapril, losartan, amlodipine, hydrochlorothiazide, or bisoprolol) for 6 months
Number of subjects: 61
Study 21917299 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 61
Study 21917299 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment changes
Number of subjects: 61
Study 19433129 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release (CR)
Number of subjects: 116
Study 19433129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 17157442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessments (EMA) of happiness
Number of subjects: 72
Study 17157442 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive and Negative Affect Schedule (PANAS)
Number of subjects: 72
Study 15036166 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Parkinson's disease (PD)
Number of subjects: 57
Study 15036166 — intervention group
Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 57
Study 12471004 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 20 micro g/kg
Number of subjects: 113
Study 12471004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 4 micro g/kg
Number of subjects: 113
Study 12471004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 9796881 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg (single dose)
Number of subjects: 21
Study 9796881 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 21